ArticleCommunications biology2026
BRD2 impedes iPSC reprogramming by regulating lipid biosynthesis and the matrisome via its ET tail.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Induction of human pluripotent stem cells (hiPSCs) from somatic cells encounters significant barriers that remain poorly understood. Lipids are fundamental cellular molecules with many essential roles. However, the roles of lipids in reprogramming are unknown. Here, we show that BRD2 is a barrier to hiPSC reprogramming by suppressing lipid genes and maintaining the somatic transcriptional program, particularly the somatic matrisome program. Strikingly, the acetylation epigenetic reader BRD2 unorthodoxly suppresses the expression of lipid-related genes in the reprogramming cells. The two rate-limiting enzymes of lipid biosynthesis, stearoyl-CoA desaturase (SCD), 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), and lipid supplements all enhance iPSC reprogramming. Interestingly, the extra terminal (ET) tail of BRD2 suppresses reprogramming and the lipid transcriptional program but positively regulates the matrisome program. In line with its transcriptional suppression of lipid genes, BRD2 binds to genes of lipid biosynthesis and negatively regulates their H3K27Ac status. These discoveries advance our molecular understanding of hiPSC reprogramming, as well as of the transcriptional regulation of matrisome and lipid programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.